Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies
June 16 2020 - 04:05PM
Business Wire
Illumina, Inc. (NASDAQ: ILMN) today announced that the U.S.
District Court for the Northern District of California issued a
preliminary injunction order against several BGI companies,
including MGI Tech Co., Ltd., Complete Genomics Inc., BGI Americas
Corp., and MGI Americas Inc. The preliminary injunction was granted
in two patent infringement lawsuits that Illumina filed against BGI
in June 2019 (Case No. 3:19-cv-03770) and February 2020 (Case No.
3:20-cv-01465).
The preliminary injunction order prohibits BGI from launching
its sequencing instruments and related reagents in the United
States. The order prohibits the supply, use or sale of both the
standard and “CoolMPS” chemistries.
“We are pleased with the Court’s decision. It validates that BGI
has blatantly copied Illumina’s proprietary sequencing chemistry,”
said Charles Dadswell, SVP and General Counsel for Illumina.
“Illumina’s patents reflect the hard work, dedication and
investment made by Illumina and its scientists, revolutionizing the
industry and dramatically driving down the cost of sequencing.”
The preliminary injunction is based on U.S. Patent Nos.
7,541,444; 7,566,537; 7,771,973; 9,410,200; and 10,480,025. The
patents cover Illumina’s proprietary sequencing-by-synthesis
chemistry. Related patent suits are pending in Denmark, Finland,
Germany, Sweden, Switzerland, Turkey, and the UK. The trial in the
US case is scheduled to begin on May 25, 2021.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200616005978/en/
Illumina, Inc. Investors: Jacquie
Ross, CFA +1-858-255-5243 IR@illumina.com or Media: Jen Carroll
858-882-6822 pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2023 to Mar 2024